Dr. Brander on the Treatment of Relapsed/Refractory CLL

Video

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Brander says there is debate about which patients with CLL will benefit from chemotherapy versus chemoimmunotherapy. The majority of patients in the relapsed/refractory setting are being transitioned to novel therapies. Currently, patients in the relapsed/refractory setting can receive ibrutinib (Imbruvica) if they did not receive it in the frontline setting, idelalisib (Zydelig) if they had more than 2 prior lines of therapy or are not eligible for other treatments, or venetoclax (Venclexta). In June 2018, venetoclax was granted a full approval by the FDA for the treatment of patients with CLL with or without 17p deletion, following at least 1 prior therapy.

There are multiple targeted inhibitors that are being tested in this population, as well. Clinical trials are investigating next-generation BTK inhibitors such as acalabrutinib (Calquence). In high-risk patients, acalabrutinib will be randomized versus ibrutinib in a phase III trial to evaluate differences in toxicity, Brander says.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD